No Data
No Data
We Think You Should Be Aware Of Some Concerning Factors In Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Earnings
Jiangsu Lianhuan Pharmaceutical (600513.SH): The company has been selected as a national-level specialized, special, and new "small giant" enterprise.
On September 9, Gelonghui announced that Jiangsu Lianhuan Pharmaceutical (600513.SH) has been successfully selected as a nationally recognized specialized and new 'Little Giant' enterprise in the sixth batch according to the 'Public Notice of the List of Enterprises for the Sixth Batch of Specialized and New 'Little Giant' Enterprises and the Third Batch of Specialized and New 'Little Giant' Enterprises Reviewed and Passed by the Jiangsu Provincial Department of Industry and Information Technology' recently released by the Jiangsu Provincial Department of Industry and Information Technology. The public notice has ended as of the date of this announcement.
Jiangsu Lianhuan Pharmaceutical (600513.SH): The company has passed an on-site inspection by the USA FDA.
On September 3, Ge Longhui announced that jiangsu lianhuan pharmaceutical (600513.SH) received an on-site inspection of cGMP (current Good Manufacturing Practice) from the U.S. Food and Drug Administration (FDA) from July 15, 2024 to July 19, 2024. Recently, the company received the Establishment Inspection Report (EIR) issued by the U.S. FDA, indicating that the company's production site has passed this cGMP on-site inspection. This successful on-site inspection by the U.S. FDA indicates that the company's...
Lianhuan Pharmaceutical 2024 Semi-Annual Report
Summary of Lianhuan Pharmaceutical\'s 2024 Semi-Annual Report
Jiangsu Lianhuan Pharmaceutical (600513.SH): The net income in the first half of the year was 62.8879 million yuan, a year-on-year increase of 2.21%.
On August 29th, Lianhuan Pharmaceutical (600513.SH) announced its semi-annual report. From January to June 2024, the company achieved revenue of 1.126 billion yuan, a year-on-year increase of 17.98%, and achieved a net income attributable to the owners of the parent company of 62.8879 million yuan, a year-on-year increase of 2.21%.
No Data
No Data